John Higgins
Board Member
OmniAb, Inc. (OABI)Equibles does not estimate personal net worth.
Get an email with a short summary when OmniAb, Inc. publishes a filing, an earnings call transcript or a press release.
Get OABI alertsAbout John Higgins
John Higgins is recorded as Board Member at OmniAb, Inc. (OABI) since January 1, 2022. The newest filing on record that lists John Higgins as Board Member at OmniAb, Inc. (OABI) is dated April 29, 2026. Earlier roles on record: Board Member at Ligand Pharmaceuticals Inc (LGND) until December 31, 2022 and CEO at Ligand Pharmaceuticals Inc (LGND) until December 5, 2022. The proxy statement of Ligand Pharmaceuticals Inc reports total compensation of $16,764,990 for John Higgins in fiscal 2022, including a base salary of $675,264. Disclosed compensation is on record for 6 fiscal years. John Higgins has spoken on 11 earnings calls across 1 company, most recently for Ligand Pharmaceuticals Inc on November 7, 2022. OmniAb, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls John Higgins spoke on are classified in the Healthcare sector. Other leadership on record at OmniAb, Inc. includes Matthew Foehr (CEO and Board Member), Matthew W. Foehr (CEO and Board Member), John L. Higgins (Chairman and Board Member) and 7 others.
John Higgins on recent calls
“I'll open the call with some remarks about our recent major strategic and financial transaction. We closed the OmniAb spinout on November 1st, just one week ago today.”
“We are executing well across the organization and are pleased to share our success this quarter, highlighted by strong royalty growth, major partner news, and good progress toward our OmniAb spin-out.”
“Good afternoon, and thanks for joining Ligand's first quarter 2022 financial results conference call. In addition to our strong financial performance, the other main highlight this past quarter is the progress we made towards separating out OmniAb into a public standalone company.”
“2021 finished strong financially and operationally. We are very pleased with our report to shareholders today and our progress and momentum in all areas of the business reinforces our plans to split Ligand into two separate public companies.”
“Today we have an outstanding quarterly report for our shareholders, with the highest ever royalties for our largest partner products. We've had a string of partner successes with several approvals in recent months, and launches are now underway that we expect will fuel growth and royalty revenue for years to come.”
Affiliation history
-
Current
2022-01-01–present
Last confirmed April 29, 2026
-
2007-01-01–2022-12-31
-
Start not stated–2022-12-05
Company network
Biotechnology · Healthcare
CEO, Board Member
2007-01-01–2022-12-31
Leadership on record at OmniAb, Inc.
- Matthew Foehr CEO, Board Member
- Matthew W. Foehr CEO, Board Member
- John L. Higgins Chairman, Board Member
- Kurt A. Gustafson CFO
- Kurt Gustafson CFO
- Amechi Nwachuku COO
- Charles S. Berkman General Counsel
- Carolyn Bertozzi Board Member
- Carolyn Bertozzi, Ph.D. Board Member
- Carolyn R. Bertozzi Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Ligand Pharmaceuticals Inc (LGND) | Former Chief Executive Officer | $675,264 | $16,764,990 |
| 2021 | Ligand Pharmaceuticals Inc (LGND) | Former Chief Executive Officer | $696,583 | $9,587,211 |
| 2020 | Ligand Pharmaceuticals Inc (LGND) | Former Chief Executive Officer | $668,333 | $5,842,767 |
| 2019 | Ligand Pharmaceuticals Inc (LGND) | Chief Executive Officer | $648,192 | $6,770,376 |
| 2018 | Ligand Pharmaceuticals Inc (LGND) | Chief Executive Officer | $627,413 | $6,306,803 |
| 2017 | Ligand Pharmaceuticals Inc (LGND) | Chief Executive Officer | $611,656 | $5,513,207 |